Medgenics (MDGN +13.2%) gets a pop today after being granted a patent by the USPTO protecting the use of the company's Epodure Biopump technology for the treatment of anemia. The patent agency also allowed claims covering a similar method for delivery underlying it's Hemodure Biopump technology for sustained prophylactic treatment of hemophilia. MDGN's global portfolio now includes 36 patents issued, with 81 more pending.
From other sites
at Nasdaq.com (Dec 4, 2014)
at MarketWatch.com (Jun 25, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs